H.C. Wainwright lowered the firm’s price target on Compass Pathways (CMPS) to $40 from $45 and keeps a Buy rating on the shares. Compass confirmed that no further development is planned in anorexia nervosa following completion of the Phase 2 trial, the analyst tells investors in a research note. As such, the firm removed the indication from its model post the Q2 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Compass Pathways’ Phase III Study on COMP360: A Potential Breakthrough in Treating Depression
- Compass Pathways Reports Strong Progress in Q2 2025
- Compass Pathways’ Earnings Call Highlights Success and Challenges
- Positive Buy Rating for COMPASS Pathways Driven by Strategic Progress and Financial Stability
- Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer in Depression Treatment